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OBJECTIVES: To characterize the real-world profile of heart failure (HF) patients
with reduced ejection fraction (REF) and their treatment patterns in China.
METHODS: A retrospective chart review was conducted in 9 hospitals in 5 key
regions (Beijing, Shanghai, Wuhan, Chengdu, Guangzhou) to capture patient pro-
files and to evaluate treatment patterns in patients following hospitalization for
HF. Patients hospitalized for HF in 2005-2008 were identified. A total of 805 HF
subjects’ charts were selected and reviewed for health care treatment between
2000 and 2011. Data were collected from the first HF hospitalization until the last
date of data entry or death. RESULTS: A total of 460 patients with HF-REF and at
least one hospitalization were followed for an average of 2.86 years. Patients were
aged 61.814.12, and 65.9% were male. On average, HF-REF patients had 2.02.30
hospitalizations during follow-up. At the first hospitalization, severity was most
frequently New York Heart Association (NYHA) Class III in 46.4% of patients, fol-
lowed by Class IV in 27.1% and Class II in 26.0%. HF severity increased with subse-
quent hospitalizations. The most common etiologic/comorbid conditions were
idiopathic dilated cardiomyopathy (49.3%) followed by hypertension (42.2%), atrial
fibrillation (24.1%) and ischemic heart disease (20.2%). Median length of stay for the
first hospitalization was 10 days with the subsequent 3 hospitalizations ranging
between 8-9 days. The overall death rate during the follow-up period was 19.35%
with regional variance; 0% in Shanghai to 32% in Wuhan; however Shanghai sub-
jects had milder HF. The mean time to death was 747.0568.9 days from first
hospitalization for thosewho died (median: 779.0).CONCLUSIONS:This large chart
review provides a recent, real-world patient profile of HF-REF patients following
hospitalization for HF in China. Heart failure treatment presents a large burden to
the health care system in the 5 major regions in China, with some regional
variations.
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OBJECTIVES: Atrial fibrillation (AF), the most common sustained arrhythmia, con-
fers an increased risk of death in patients with myocardial infarction (MI). The
onset of AF in relation to MI differentially impacts survival, with AF developing
after MI corresponding to the worst survival. However, the impact of AF and its
timing on healthcare resource utilization after MI is unknown.METHODS: The risk
of hospitalization, emergency department (ED) visits, and outpatient office visits
associated with prior, early-onset (30 days post-MI) and late-onset (30 days
post-MI) AF was assessed among incident MI patients from 2002–2009 in the com-
munity. Andersen-Gill modeling was used to predict hospitalizations and ED visits
by AF category, whereas negative binomial regression was used for outpatient
visits. RESULTS: Of 1362 MI patients (mean age 6815, 57%men), 221 had prior AF,
134 developed early-onset AF, 96 developed late-onset AF, and 911 had no AF. Over
a mean of 3.7 years, 3335 hospitalizations, 4940 ED visits, and 70,632 outpatient
visits occurred. After adjustment, as compared to those without AF, patients with
prior and early-onset AF exhibited a 1.5-fold and 1.3-fold increased risk of hospi-
talization, respectively. In contrast, late-onset AF carried a 2.1-fold increased risk of
hospitalization. The corresponding hazard ratios for ED visits were 1.4, 1.2, and 1.7
for prior, early-onset, and late-onset AF, respectively. Surprisingly, the risk of out-
patient visits did not differ by the timing of AF, and only a 1.3-fold increased risk
was observed for late-onset AF.CONCLUSIONS:AmongpatientswithMI, the risk of
subsequent hospitalizations and ED visits differed markedly according to the tim-
ing of AF, with approximately twice the risk among those developing late-onset AF
compared to MI patients without AF. AF is an adverse prognostic indicator in MI
and these data underscore the importance of its management in MI patients.
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OBJECTIVES: To evaluate the profile of patients undergoing hip replacement (THR)
or knee replacement (TKR) surgery and the associated costs with surgery according
to public health care system (SUS) perspective. METHODS: A review of a govern-
ment administrative claims database (DATASUS) was conducted for patients who
underwent a THR or TKR procedure between January 2009 to March 2011. Data
regarding gender, age and mean costs per patients were analyzed for the entire
period and data for procedures costs were collected per year, as some of themwere
excluded from SUS procedure list. RESULTS: A total of 41,862 patients were iden-
tified at study period (12,476 for TKR and 29,386 THR). Average agewas 65,6 (SD 10,5)
for TKR and 64,1(SD 14,9) for THR, being women more frequently submitted to
surgery than men (71,7% vs 28,3% for TKR and 55,7% vs 44,3% for THR). Mean
hospitalizations costs per patient was $BRL4,203 (SD $BRL2,115) and $BRL4,130 (SD
$BRL2,145) for TKR and THR respectively. When comparing expenses according to
procedures groups, prostheses represented 76,9% and 76,8% of total costs in 2009
and 2010 respectively, followed by health care professionals. CONCLUSIONS:More
than 40,000 total arthroplasty surgeries were performed in SUS from January 2009
until March 2011, when THR accounted for approximately 70% of all cases. Mean
age for patients submitted to surgery were similar for both procedures, being
women more frequently undertaking surgery than man. When considering all
costs associated to arthroplasty, total expenses were similar in both groups. How-
ever, when compared with costs reported at the private system (described else-
where), expenses in SUS represents about 12%.
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OBJECTIVES: Acute heart failure (AHF) is a mounting problem worldwide, with
significant economic burden. Renal impairment is common among patients with
AHF but its full economic implications are unknown. The study aims to describe
and compare medical resource utilization and costs among AHF patients with and
without renal impairment.METHODS: Patients with1 hospitalization with a pri-
mary diagnosis of AHF continuously enrolled for 6 months of baseline period
prior to the first hospitalization (FH) were identified in the US MarketScan claims
database (2004-2008). History of renal impairmentwas identified using ICD-9 codes
at baseline or FH. Patients were observed for 12 months post FH or until insurance
disenrollment. Measured outcomes include inpatient resource utilization, hospital
length of stay (LOS) and costs. Rates of hospital re-admissions, outpatient visits
and costs were calculated per patient per month (PPPM). RESULTS: A total of 6396
AHF patients (mean age 73.6 years, 50.6% female) were studied; 1082 (17%) had
renal impairment. At FH, renal patients hadmore comorbidities, longer LOS (7.0 vs.
7.9 days), and similar costs ($15,820 vs. $15,467) compared to non-renal patients.
The average cost per re-hospitalization was $17,887 vs. $16,780 for renal vs. non-
renal patients, with average LOS of 7.9 and 6.5 days, respectively. Throughout the
study period, re-hospitalization, outpatient visit rates and costs PPPM were signif-
icantly (P0.05) higher among renal compared to non-renal patients, with highest
costs and rates observed within 3 months of FH ($2,480 vs. $1,421 total healthcare
cost PPPM; 0.063 vs. 0.024 re-hospitalization PPPM and; 1.406 vs. 1.051 outpatient
visits PPPM). CONCLUSIONS: AHF patients with renal impairment are resource
intensive and a costly subgroup of AHF population. Their increased use of outpa-
tient services despite having longer, more frequent hospitalizations suggest an
unmet need thus, new therapies that reduce re-hospitalizations may offer mean-
ingful cost savings and improved health outcomes.
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OBJECTIVES: As the primary care sector does not bear the direct costs of hospital-
ization, it may under-invest in prevention to avoid hospitalizations. This could
increase overall primary care spending if hospitalizations are associated with sub-
sequent increases in primary care resource use. The objectives of this studywere to
compare the number of primary care visits one year before and after a hospitaliza-
tion, within hospitalized patients, and between non-hospitalized and hospitalized
patients (post hospitalization). METHODS: Data on hospital and primary care re-
source use among hypertensive patients (17 years) were extracted from elec-
tronic patient journals from 1999 through 2007. Differences in number of visits
prior to and post hospitalization, and between hospitalized and non-hospitalized
patients, were assessed using standard statistical tests. Propensity-scorematching
was used to account for differences in observable characteristics.RESULTS:Among
10,196 patients, 4,692 patients were hospitalized and 5,504 were not hospitalized.
During the year prior to hospitalization, hospitalized patients had a significantly
lower (p0.0001) mean number (SD) of total visits than in the post-hospitalization
year: 4.58 (7.75) versus 6.91 (12.12). Non-hospitalized patients had significantly
fewer (p0.0414) visits than hospitalized patients (post-hospitalization): 4.46 (4.28)
versus 6.91 (12.12). Results were qualitatively similar for GP and nurse visits, in
different subgroups (e.g. age, diabetes), and in patients without prior cardiovascu-
lar disease or cancer. Also when comparing propensity-matched (e.g. gender, geo-
graphic region) hospitalized and non-hospitalized patients, results remained sim-
ilar. The number of visits demonstrated a rising trend prior to hospitalization and
peaked during the three months post hospitalization. After three months, the
number of visits decreased yet stabilized at a higher level than before
hospitalization.CONCLUSIONS:Weshow that hospitalizations are associatedwith
significant subsequent increases in primary care resource use. This suggests that
investing in treatments that prevent hospitalizations could potentially reduce
overall costs in primary care while improving patient health.
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OBJECTIVES: To determinemedical resource utilization and costs following hospi-
talization among elderly patients with chronic heart failure (HF). METHODS: Pa-
tients 65 years and older, with 1 hospitalization with a chronic HF diagnosis
(ICD-9 428.22, 428.32 or 428.42) were identified in the MarketScan® database be-
tween 2004 and 2008. Patients were observed starting 6 months prior to index
chronic HF hospitalization (IH) until disenrollment or end of data availability. Re-
source use and costs during IH and subsequent 4 HF re-hospitalizations were cal-
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culated. Per patient per month (PPPM) utilization rates were calculated based on
inpatient, outpatient and prescription data, and costs were estimated using Medi-
care reimbursement rates and Average Wholesale Price. RESULTS: A total of 5741
patientsmet the inclusion criteria. At least one HF re-hospitalizationwas observed
in 25% of patients, representing 85% of all-cause hospitalizations. Mean HF hos-
pital length of stay was 6.7 days at IH and 7.2 days at fourth HF re-hospitalization.
IH was most costly ($12,426) relative to the mean cost per subsequent HF re-hos-
pitalization ($9,832). HF re-hospitalization rates peaked at 0.062 PPPM 3-6 months
post IH. All-cause and HF-related outpatient visit rates peaked at 4.1 and 0.65 visits
PPPM, respectively, within threemonths after IH.Mean outpatient visit cost ranged
from$668 (0-3months) to $224 (18-24months post IH). Total pharmacy costs varied
from $593 PPPM (baseline period) to $848 PPPM (0-3 months post IH); of these,
cardiovascular drugs accounted for about one third ranging from $162 (baseline) to
$221 PPPM (0-3 months post IH). CONCLUSIONS: Treating elderly chronic HF pa-
tients is resource intensive and costly. Utilization and cost peak in the first three
months post IH. New interventions to improve health outcomes in the elderly HF
population hold the potential to decrease post IH resource utilization and save
costs.
PCV103
VIP BRAZIL: RESOURCE USE AND ASSOCIATED COSTS OF THROMBOTIC
EVENTS AFTER TOTAL KNEE REPLACEMENT (TKR) SURGERY IN BRAZILIAN
PUBLIC HEALTH CARE SYSTEM (SUS)
Nita ME1, Comparini LB1, Mainine S2, Santinho CS1, Fujii RK3, Mussolino F4, Rached R1,
Rahal E1
1Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 2Hospital Estadual Mario Covas, Santo Andre,
Sao Paulo, Brazil, 3Pfizer, Inc., São Paulo, São Paulo, Brazil, 4NEW BD - Business Developers, São
Paulo, SP, Brazil
OBJECTIVES: Patients undergoing total knee or hip replacement are at high risk of
experiencing venous thromboembolism (VTE) - deep vein thrombosis (DVT) and
pulmonary embolism (PE), therefore, the aimof this studywas to estimate resource
utilization and associated costs of VTE following TKR under SUS perspective.
METHODS:Data analysis was conducted through a review of a government admin-
istrative claims database (DATASUS). A cohort of patients who underwent TKR
surgery in the public healthcare systemwas defined (1/2010 - 9/2010) and followed
for 6 months after surgery. Data regarding total hospitalization costs were com-
pared for patients who didn’t present complications with patients who presented
VTE events.RESULTS:A total of 4736 patientswere identified between January 2010
to September 2010 with average age of 65,6 years (SD 10,3), being 72.1% female.
Mean hospitalization costs per patientwere $BRL4,036 (SD 2,063) for the population
analyzed. VTE episodes were experienced by 42 patients (0,89%, 32 cases of DVT
and 10 of PE) and were associated with higher hospitalizations costs than patients
without any complication: $BRL3,919 (SD 1,811), $BRL4,581 (SD 2,362) and
$BRL7,715 (SD 6,777) for patients without complication, DVT and PE respectively.
CONCLUSIONS: Patients experiencing VTE following TKR surgery represents a sig-
nificant economic burden for the Brazilian public health care system. Our study
suggests that a patient who presents PE following TKR surgery can cost twicemore
than a patient without complications.
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OBJECTIVES: Hypertension is the most important risk factor in the preventable
cardiovascular risks. In the study, consumption analysis of the products contains
ARB and ACEI was performed and factors effecting the budget chance was calcu-
lated with a regression analysis for assessment the current situation.METHODS:A
computer base analysis was conducted depending on consumption data of ARB
and ACEI which were taken from Information Medical Statisticis – Health (IMS) in
2005-2010 years by using Windows Office Excel 2007. Regression analysis was per-
formed with the results of conducted analysis by using SPSS 15.00 for Windows.
RESULTS: Losartan consumption in unit, however, was rised 40%, consumption in
TL was decreased 47% in years. Consumption of Ramipril molecule in unit rised
71,2% and TL consumption decreased 31,7% from year 2005 to 2010, even the pos-
itive marketing effects of new generic molecules were launched. It was shown in
the regression analysis that new launched generics had a negative effect to budget
of ARB and ACEI. The formula of percentage chance of the budget of ARB and ACEI
market was calculated as PCB  NPLY*(-0,07)  PCY*(1,248)  CC*(0,936). BC: Per-
centage Chance of Budget, NPLY: New Product Number Launched in Years, PCY 
Percentage Chance of Price in Years, CC  Percentage Chance of Consumption in
Years. CONCLUSIONS: Effect of hypertension to Turkey‘s health budget is rising
day by day due both rising diagnosis and comorbidites. On the other hand, it was
shown that launching new generics has an important impact on controlling health
budget.
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OBJECTIVES: Aim of this study was to evaluate the average annual direct costs of
treating patients with a recent admission for acute coronary syndrome (ACS).
METHODS: Direct medical costs of patients with ACS (index event) in the period
January 1, 2008 to December 31, 2008 and treated with dual antiplatelet therapy
(clopidogrelaspirin)were estimated in a one-year follow-upperiod. Resource con-
sumption measured were: reimbursed drugs, diagnostic procedures, hospitaliza-
tions. The analysis was performed from the Italian National Health Service (INHS)
perspective. RESULTS: A total of 2,758,872 subjects were observed; 7,082 (35.8%
females) of thesewere hospitalized for ACSduring the 1-year accrual period (2.6‰).
Among patients with ACS, 60% were medically treated, 33.1% were treated with
percutaneous coronary intervention (PCI) and 6.9% died during the first hospital-
ization. Dual antiplatelet treatment was prescribed in 25.9% of patients with ACS
medically treated and in 70.1% of patients with ACS treated with PCI. During fol-
low-up, all-cause mortality rate was 5.7% [33% for cardiovascular (CV) causes];
among the 58.6% of patients with at least one re-hospitalization, 18.4% had a re-
current episode of ACS, 24.8% had other CV episodes and 15.4% were hospitalized
for non-CV reasons. Average yearly cost/patient for total ACS population was
12,673€/year (drugs: 1,896€, hospitalizations: 10,315€, diagnostic: 462€). For patients
with an index event of ACS medically treated, average annual cost was 11,043€/
year (drugs: 1,968€, hospitalizations: 8,558€, diagnostic: 517€) and for patients with
ACS treated with PCI, average annual cost per patient was 13,776€/year (drugs:
1,848€, hospitalizations: 11,492€, diagnostic: 436€). Hospitalization costs of patients
with a relapse were at least 49% higher than for patients without events. Patients
died for a CV event during follow-up had an average cost of 19,198€/patient.
CONCLUSIONS: Patients with ACS had relevant costs of management being the
need for a new hospitalization the major cost driver.
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OBJECTIVES: Traditionally, newly referred naïve anticoagulation patients (warfa-
rin use for2 months) received anticoagulation education via 30-min face-to-face
pharmacist counseling (Method I).We hypothesized that a new education program
with 15-min video education plus 15-min face-to-face pharmacist counseling
(Method II) would maximize operational revenues via increased scheduling capac-
ity leading to increased clinic visits while maintaining clinic efficiency and quality
education. This study aimed to compare operational revenues, clinical outcomes
and anticoagulation knowledge levels in patients receiving two anticoagulation
education methods. METHODS: This IRB-approved study employed a parallel-
group, pre-post design. Knowledge levels were evaluated using the previously val-
idated Short-form Oral Anticoagulation Knowledge Test (SOAK) before and after
education. Revenues and clinical outcomes were measured during the implemen-
tation of Method I or II. A sample size of 106 patients was required to detect a 15%
change in knowledge with 80% power and alpha of 0.05. RESULTS: There were 108
patients (Method I:II54:54) with similar baseline demotaphics: female (52.3%),
65 years-old (52.8%) and high school education (67.9%). Clinical measures re-
main stable between twoMETHODS:major bleeding rate (0.3%), thromboembolism
rate (0.4%) and patients within target INR (63%). A 3.39% increased monthly rev-
enues was observed in Method II compared to Method I, due to increased clinic
visits (12.97%) among newly referred naïve patients, yet total patient volume of
other types decreased (-2.95%). The pre-visit SOAK scores were similar between
Methods (p0.383). Both Methods significantly improved SOAK scores (Method I:
pre 55.9%26%/post 75.8%21%, p0.001; Method II pre 60.4%26%/post
70.7%22%, p0.030). Mean changes in pre-post SOAK scores were significantly
higher in Method I (21%23%) than in Method II (10%23%, p0.011).
CONCLUSIONS: The new education program (Method ii) resulted in increased rev-
enues via increased clinic visits among newly referred patients. Improved antico-
agulation knowledge levels using Method II were acceptable without adverse im-
pacting on safety and clinical outcomes.
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OBJECTIVES: Pharmacists play an integral role in quality improvement programs
through medication therapy management services (MTM). This study estimates
the effect of a pharmacist-led and delivered MTM program on achieving Optimal
Diabetes Care (ODC). METHODS: The study included patients with diabetes who
receivedMTM services at Fairview Clinics during a 2007 demonstration project (n
121) and those invited to receive MTM services but opted out (n 103). Baseline
characteristicswere compared between the two groups. Rates of ODC for 2006, 2007
and 2008 were compared using McNemar’s test based on Minnesota Community
Measurement all-or-none 5-component (D5) ODC measure (HbA1c 7%;
LDL100mg/dl; blood pressure140/90mmHg; tobacco free; and daily aspirin use).
Linear and Nonlinear multivariate difference-in-differences (DID) estimation were
used to evaluate the impact of one-year exposure toMTMon each component of D5
ODCmeasure. RESULTS: The MTM group had more co-morbidities, more complex
medication regimens and a higher percentage of diabetes with complications
(p0.05). There was significant improvement in ODC rates for the MTM group in
2007 compared to 2006 (45.45%vs.21.49%, p0.001) and a significant decline in 2008
(45.45% vs. 25.62%, p0.0002). The control group showed a significant improve-
A131V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
